Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine held its 2026 annual stockholder meeting, where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Connaughton received 28,660,181 votes for and 10,789,549 withheld, while Levy received 37,095,058 votes for and 2,354,672 withheld, in each case with 26,404,190 broker non-votes.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 32,914,258 votes for, 6,322,885 against, 212,587 abstentions, and 26,404,190 broker non-votes. In addition, they ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 64,686,839 votes for, 774,471 against, and 392,610 abstentions.
Editas Medicine, Inc. senior vice president and chief financial officer Amy Parison reported an open-market sale of 464 shares of common stock on June 3, 2026 at a weighted average price of $2.7010 per share. According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 7, 2022 and was made to satisfy tax withholding obligations arising from vesting of restricted stock units on June 2, 2026, rather than as a discretionary trade. Following this transaction, she directly holds 14,970 shares of Editas Medicine common stock.
Editas Medicine CEO O'Neill Gilmore Neil reported an automatic, tax-related share sale. On June 3, 2026, he sold 15,380 shares of common stock at a weighted average price of $2.7011 per share, leaving 248,313 shares owned directly.
The sale was executed under a durable automatic sales instruction plan adopted on April 13, 2022, and was made to cover tax withholding obligations from restricted stock units that vested on June 2, 2026. The footnote states this was not a discretionary trade by the CEO.
Editas Medicine, Inc. executive Linda Burkly reported an open-market sale of common stock. She sold 731 shares on June 3, 2026 at a weighted average price of $2.7011 per share. After this transaction, she directly holds 67,297 shares of Editas Medicine common stock.
According to the footnotes, the sale was carried out under a durable automatic sales instruction plan adopted on July 3, 2023. The shares were sold to cover tax withholding obligations arising from restricted stock units that vested on June 2, 2026, and the filing states the trade was not discretionary.
Editas Medicine ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report shared beneficial ownership of 8,889,000 shares of Editas Medicine common stock. The filing states this equals 5.8% of shares outstanding based on 153,461,838 shares outstanding as of May 27, 2026.
The Fund directly holds 8,889,000 shares and has delegated sole voting and dispositive power to RA Capital; the Reporting Persons disclaim beneficial ownership except for Section 13(d) purposes.
Editas Medicine, Inc. ownership disclosure: TCG Crossover III entities and Chen Yu report shared beneficial ownership of 15,798,999 shares of Common Stock, representing 9.9% of the class. The total counts include 11,111,111 issued shares plus 4,687,888 shares issuable upon warrants exercisable within 60 days. The filing cites 153,461,838 shares outstanding as of May 27, 2026 following an underwritten offering, and a combined basis of 158,149,726 shares when the exercisable warrants are included.
The reporting persons note a Beneficial Ownership Limitation that prevents exercise of certain warrants to the extent doing so would push ownership above 9.99%. The filing is a joint Schedule 13G by TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC and Chen Yu and includes a joint filing agreement.
Editas Medicine reports a joint Schedule 13G showing Commodore Capital entities and two managing partners may be deemed to beneficially own 16,045,802 shares of common stock, comprising 8,889,000 shares plus rights to 7,156,802 shares underlying common warrants. The filing states ownership percentages are based on 153,461,838 shares outstanding as of May 21, 2026 and that a Beneficial Ownership Limitation of 9.99% applies. The report names Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz as filers and notes shared voting and dispositive power over the disclosed securities.
EDIT notice of proposed resale of Common Stock by an insider. The filing lists 15,000 shares and an associated $46,200 figure, with an exchange noted as NASDAQ and an effective date of 06/03/2026. The filing also records Restricted Stock Unit Vesting of 32,957 shares on 06/02/2026 and a prior sale of 5,394 shares on 03/03/2026 for $10,894.26.
Editas Medicine is offering 55,555,556 shares of common stock and accompanying warrants at a combined public offering price of $2.25 per share-plus-warrant. The offering includes detachable common stock warrants exercisable at $3.50 (or pre-funded alternatives) and is expected to raise approximately $117.0 million in net proceeds to fund development of EDIT-401, clinical and manufacturing costs, and general corporate purposes. The offering assumes 153,461,838 shares outstanding after the offering (assuming no exercise of the new warrants).
Editas Medicine is offering 55,555,556 shares of common stock and accompanying warrants at a combined public offering price of $2.25 per share-plus-warrant. The offering includes detachable common stock warrants exercisable at $3.50 (or pre-funded alternatives) and is expected to raise approximately $117.0 million in net proceeds to fund development of EDIT-401, clinical and manufacturing costs, and general corporate purposes. The offering assumes 153,461,838 shares outstanding after the offering (assuming no exercise of the new warrants).
Editas Medicine is offering 55,555,556 shares of common stock and accompanying warrants at a combined public offering price of $2.25 per share-plus-warrant. The offering includes detachable common stock warrants exercisable at $3.50 (or pre-funded alternatives) and is expected to raise approximately $117.0 million in net proceeds to fund development of EDIT-401, clinical and manufacturing costs, and general corporate purposes. The offering assumes 153,461,838 shares outstanding after the offering (assuming no exercise of the new warrants).
Editas Medicine entered into an underwriting agreement for an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants, with each share-plus-warrant unit priced at $2.25. All securities are being sold by the company under an effective shelf registration.
The company expects net proceeds of about $117.0 million after underwriting discounts and expenses, excluding any warrant exercise proceeds. Management estimates that, combined with cash and cash equivalents as of March 31, 2026, this funding will support operations into the second half of 2028, though this outlook depends on assumptions that may change.
Editas Medicine entered into an underwriting agreement for an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants, with each share-plus-warrant unit priced at $2.25. All securities are being sold by the company under an effective shelf registration.
The company expects net proceeds of about $117.0 million after underwriting discounts and expenses, excluding any warrant exercise proceeds. Management estimates that, combined with cash and cash equivalents as of March 31, 2026, this funding will support operations into the second half of 2028, though this outlook depends on assumptions that may change.
Editas Medicine entered into an underwriting agreement for an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants, with each share-plus-warrant unit priced at $2.25. All securities are being sold by the company under an effective shelf registration.
The company expects net proceeds of about $117.0 million after underwriting discounts and expenses, excluding any warrant exercise proceeds. Management estimates that, combined with cash and cash equivalents as of March 31, 2026, this funding will support operations into the second half of 2028, though this outlook depends on assumptions that may change.